Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline Review, H2 Pharmaceutical Research Report 2017

Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline Review, H2 2017”. Idiopathic thrombocytopenic purpura is a bleeding disorder in which the immune system destroys platelets, which play important role in normal blood clotting.

Request For Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1305515

Symptoms include blood in urine or stools, fatigue, spontaneous bleeding from nose and superficial bleeding into skin that appears as a rash of pinpoint sized reddish purple spots, usually on lower legs.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 5, 8, 3, 2 and 7 respectively.

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders).
– The pipeline guide reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Browse Full Report With TOC: http://www.marketresearchhub.com/report/idiopathic-thrombocytopenic-purpura-immune-thrombocytopenic-purpura-pipeline-review-h2-2017-report.html

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Overview 6
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Products under Development by Companies 11
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Therapeutics Assessment 14
Assessment by Target 14
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Companies Involved in Therapeutics Development 22
3SBio Inc 22
Amgen Inc 22
arGEN-X BV 23
Biogen Inc 23
Boehringer Ingelheim GmbH 24
Bristol-Myers Squibb Company 24
CSL Ltd 25
Dova Pharmaceuticals Inc 25
Enzene Biosciences Ltd 26
Genosco Inc 26
GlaxoSmithKline Plc 27
Hansa Medical AB 27
Immunomedics Inc 28
Intas Pharmaceuticals Ltd 28
Jiangsu Hengrui Medicine Co Ltd 29
Momenta Pharmaceuticals Inc 30
Novartis AG 31
Pfizer Inc 32
Pharmagenesis Inc 32
Protalex Inc 33
Rigel Pharmaceuticals Inc 33
UCB SA 34
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Drug Profiles 35
avatrombopag – Drug Profile 35
belimumab – Drug Profile 38
BI-655064 – Drug Profile 46
efgartigimod alfa – Drug Profile 48
eltrombopag olamine – Drug Profile 51
eltrombopag olamine – Drug Profile 58
fostamatinib disodium – Drug Profile 59
GL-2045 – Drug Profile 65
Hetrombopag Olamine – Drug Profile 67
KLM-465 – Drug Profile 68
letolizumab – Drug Profile 70
M-230 – Drug Profile 71
M-254 – Drug Profile 72
M-281 – Drug Profile 73
PBF-1650 – Drug Profile 74
PHN-013 – Drug Profile 75
PRTX-100 – Drug Profile 76
Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases – Drug Profile 83
rituximab – Drug Profile 84
romiplostim – Drug Profile 91
romiplostim biosimilar – Drug Profile 95
romiplostim biosimilar – Drug Profile 96
rozanolixizumab – Drug Profile 97
SKIO-703 – Drug Profile 98
thrombopoietin – Drug Profile 100
veltuzumab – Drug Profile 101
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Dormant Projects 105
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Discontinued Products 106
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Product Development Milestones 107
Featured News & Press Releases 107
Appendix 117
Methodology 117
Coverage 117
Secondary Research 117
Primary Research 117
Expert Panel Validation 117
Contact Us 117
Disclaimer 118

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1305515

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact–

90 State Street,

Albany, NY 12207,

United States

Toll Free : 800-998-4852 (US-Canada)

Email : press@marketresearchhub.com

Website : http://www.marketresearchhub.com/

Read Industry News at – https://www.industrynewsanalysis.com/

Designed by CyFocus.com
Powered by CyFocus.net